维普中文期刊产品整合服务
201篇 您的检索式:作者名="Carrat"
    题名 作者 年代 出处 被引量
1A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes显示文摘AIM:To investigate the effectiveness of antioxidant compounds in modulating mitochondrial oxidative alterations and lipids accumulation in fatty hepatocytes.METHODS:Silybin-phospholipid complex containing vitamin E(Realsil) was daily administered by gavage(one pouch diluted in 3 mL of water and containing 15 mg vitamin E and 47 mg silybin complexed with phospholipids) to rats fed a choline-deprived(CD) or a high fat diet [20% fat,containing 71% total calories as fat,11% as carbohydrate,and 18% as protein,high fat diet(HFD)] for 30 d and 60 d,respectively.The control group was fed a normal semi-purified diet containing adequate levels of choline(35% total calories as fat,47% as carbohydrate,and 18% as protein).Circulating and hepatic redox active and nitrogen regulating molecules(thioredoxin,glutathione,glutathione peroxidase),NO metabolites(nitrosothiols,nitrotyrosine),lipid peroxides [malondialdehyde-thiobarbituric(MDA-TBA)],and pro-inflammatory keratins(K-18) were measured on days 0,7,14,30,and 60.Mitochondrial respiratory chain proteins and the extent of hepatic fatty infiltration were evaluated.RESULTS:Both diet regimens produced liver steatosis(50% and 25% of liver slices with CD and HFD,respectively) with no signs of necro-inflammation:fat infiltration ranged from large droplets at day 14 to disseminated and confluent vacuoles resulting in microvesicular steatosis at day 30(CD) and day 60(HFD).In plasma,thioredoxin and nitrosothiols were not significantly changed,while MDA-TBA,nitrotyrosine(from 6 ± 1 nmol/L to 14 ± 3 nmol/L day 30 CD,P < 0.001,and 12 ± 2 nmol/L day 60 HFD,P < 0.001),and K-18(from 198 ± 20 to 289 ± 21 U/L day 30 CD,P < 0.001,and 242 ± 23 U/L day 60 HFD,P < 0.001) levels increased significantly with ongoing steatosis.In the liver,glutathione was decreased(from 34.0 ± 1.3 to 25.3 ± 1.2 nmol/mg prot day 30 CD,P < 0.001,and 22.4 ± 2.4 nmol/mg prot day 60 HFD,P < 0.001),while thioredoxin and glutathione peroxidase were initially increased and then decreased.Nitrosothiols were constantly increased.MDA-TBA levels were five-fold increased from 9.1 ± 1.2 nmol/g to 75.6 ± 5.4 nmol/g on day 30,P < 0.001(CD) and doubled with HFD on day 60.Realsil administration significantly lowered the extent of fat infiltration,maintained liver glutathione levels during the first half period,and halved its decrease during the second half.Also,Realsil modulated thioredoxin changes and the production of NO derivatives and significantly lowered MDA-TBA levels both in liver(from 73.6 ± 5.4 to 57.2 ± 6.3 nmol/g day 30 CD,P < 0.01 and from 27.3 ± 2.1 nmol/g to 20.5 ± 2.2 nmol/g day 60 HFD,P < 0.01) and in plasma.Changes in mitochondrial respiratory complexes were also attenuated by Realsil in HFD rats with a major protective effect on Complex Ⅱ subunit CII-30.CONCLUSION:Realsil administration effectively contrasts hepatocyte fat deposition,NO derivatives formation,and mitochondrial alterations,allowing the liver to maintain a better glutathione and thioredoxin antioxidant activity.Ignazio Grattagliano Catia V Diogo Maria Mastrodonato Ornella de Bari Michele Persichella David QH Wang Adriana Liquori Domenico Ferri Maria Rosaria Carratù Paulo J Oliveira Piero Portincasa 2013World Journal of Gastroenterology2013,19,20:6
2Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study显示文摘Laurent Beaugerie Nicole Brousse Anne Marie Bouvier Jean Frédéric Colombel Marc Lémann Jacques Cosnes Xavier Hébuterne Antoine Cortot Yoram Bouhnik Jean Pierre Gendre Tabassome Simon Marc Maynadié Olivier Hermine Jean Faivre Fabrice Carrat 2009The Lancet . 2009 (9701)2009,,:4
3Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease显示文摘Laurent Peyrin–Biroulet Kiarash Khosrotehrani Fabrice Carrat Anne–Marie Bouvier Jean–Baptiste Chevaux Tabassome Simon Frank Carbonnel Jean–Frédéric Colombel Jean–Louis Dupas Philippe Godeberge Jean–Pierre Hugot Marc Lémann Stéphane Nahon Jean–Marc Sabaté 2011Gastroenterology2011,,5:3
4Therapeutic targeting of the mTOR ‐signalling pathway in cancer: benefits and limitations显示文摘M Moschetta A Reale C Marasco A Vacca M R Carratù 2014Br J Pharmacol2014,,:2
5Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis显示文摘Benjamin Terrier Fabrice Carrat Guillaume Geri Stanislas Pol Lionel Piroth Philippe Halfon Thierry Poynard Jean-Claude Souberbielle Patrice Cacoub 2011Journal of Hepatology2011,,4:2
6Time lines of Infectionand disease in human influenza:a review of Volunteer challengestudies显示文摘Carrat F Vergu E Ferguson NM et a1 2008Am J Epidemiol2008,167,7:1
7Primary biliary cirrhosis:incidence and predictive factors of cirrhosis development in ursodidol treated patients显示文摘CORPECHOT C CARRAT F PUNPON R 2002Gastroenterology2002,122,:1
8Health care-associated pneumonia requiring hospital admission:epidemiology,antibiotic therapy,and clinical outcomes显示文摘Carratalà J Mykietiuk A Fernández-Sabé N 0,,:1
9Recent advances in the study of epigenetic effects induced by the phycotoxin okadaic acid显示文摘Edmond Ekué Creppy Adama Traoré Isabelle Baudrimont Marta Cascante Maria-Rosaria Carratú 2002Toxicology2002,,:1
10Liver biopsy: The best, not the gold standard显示文摘Pierre Bedossa Fabrice Carrat 2008Journal of Hepatology2008,,1:1
11Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease显示文摘Harry Sokol Laurent Beaugerie Marc Maynadié David Laharie Jean‐Louis Dupas Bernard Flourié Eric Lerebours Laurent Peyrin‐Biroulet Matthieu Allez Tabassome Simon Fabrice Carrat Nicole Brousse 2012Inflamm Bowel Dis2012,,11:1
12Influenza and influenza-like illness in general practice:drawing lessons for surveillance from a pilot study in Paris,France显示文摘Carrat F Tachet A Housset B 1997Br J Gen Pract1997,47,417:1
13Antinutritional effects of fumonisin B1 and pathophysiological consequences显示文摘Carratù MR Cassano T Coluccia A 2003Toxicol Lett2003,,:1
14The detect of ursodeoxzycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis 显示文摘CORPECHOT C CARRAT F BONNAND AM 2000Hepatology2000,32,:1
15An effect of ur-sodeoxyeholieacid therapy on liver fibrosis progression in pri mary biliary eirrhosis显示文摘Corpechot C Carrat F Bonnand A 2000Hepatology2000,32,12:1
16Time lines of infection and disease in human influenza: a review of volunteer challenge studies 显示文摘Carrat F Vergu E Ferguson NM 2008Am J Epidemiol2008,167,7:1
17Interferon alpha-producing cells are localized in gut-associated lymphoid tissues in transmissible gastroenteritis virus (TC-EV) infected piglets 显示文摘RIFFAULT S CARRAT C VAN REETH K 2001Vet Res2001,32,:1
18Severe accidental hypothermia treated in an ICU prognosis and outcome显示文摘Vassal T Benoit-Gonin B Carrat F 2001Chest2001,120,6:1
19Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease显示文摘Anthony Lopez Morgane Mounier Anne-Marie Bouvier Fabrice Carrat Marc Maynadié Laurent Beaugerie Laurent Peyrin-Biroulet 2014Clinical Gastroenterology and Hepatology2014,,:1
20Health care-associated pneumonia requiring hospital admission:epidemiology,antibiotic therapy,and clinical outcomes显示文摘Carratalà J Mykietiuk A Fernández-Sabé N 2007Arch Intern Med2007,167,:1
返回顶部 每页显示:
共11页 首页 上一页 第1页 下一页 末页 /11 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费